0.20 (0.14%) 1d
(A Top Pick Mar 10/20, Up 22%) National diagnostic and testing in US and Canada. Picked this for covid mass testing capabilities. Stock has done reasonably well. Still cheap and cheaper than in March due to growing into valuation. 7.8x EBITDA, 23% ROE and 12x earnings. Great balance sheet. Low pay out ratio, smaller yield.
medical services

Unlock the latest expert's opinion. Its free

Create a FREE account to see the latest opinions & get alerts about when to buy, sell or hold stocks

Unlock opinion & get signals
Integrated task system in the defense sector. Interesting drone technology. Flying under the radar, a number of irons in the fire. The contract pipeline can be lumpy. One to watch.
medical services
Benefits from the coronavirus. They run a national lab diagnostics and testing business. They have an immediate tailwind from the US about to mass-test people for the virus. Good price momentum, low-vol and trades at a 14% ROE at a so-so 20x earnings. (Analysts’ price target is $112.79)
medical services
Management couldn't give visibility into the business, so he sold it. Dominant national player. Have an opportunity to make further acquisitions. Will reassess this summer.
medical services
Diagnostic laboratory. Trades at about 7X cash flow. 9.4% free cash flow yield. Good leverage to the economy. Do about 5,000 patient tests daily. Clinics are nation wide and reach about 50% of doctors and hospitals..
medical services
A leading laboratory and diagnostic business. Less susceptible to changes that could occur in the health sector in the US. Very profitable with a lot of free cash flow. Very defensive.
medical services
Laboratory testing. The leader in the United States. Fits in well with demographics and growth in diagnostic testing. Recently lost a contract with United Health, which took the stock down 20%. Good price. Great long-term position.
medical services
(A Top Pick Aug 31/05. Down 1.5%.) Took a big drop in October and bought more. A fabulous cash flow machine. A good long term holding.
medical services
The biggest medical lab in the US. Likes the demographic play. A fixed asset base and the revenue just comes out and churns into profits. A free cash flow machine. At about 15.5 X earnings.
medical services
Showing 1 to 9 of 9 entries
  • «
  • 1
  • »

Quest Diagnostics Inc.(DGX-N) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Quest Diagnostics Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Quest Diagnostics Inc.(DGX-N) Frequently Asked Questions

What is Quest Diagnostics Inc. stock symbol?

Quest Diagnostics Inc. is a American stock, trading under the symbol DGX-N on the New York Stock Exchange (DGX). It is usually referred to as NYSE:DGX or DGX-N

Is Quest Diagnostics Inc. a buy or a sell?

In the last year, there was no coverage of Quest Diagnostics Inc. published on Stockchase.

Is Quest Diagnostics Inc. a good investment or a top pick?

Quest Diagnostics Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Quest Diagnostics Inc..

Why is Quest Diagnostics Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Quest Diagnostics Inc. worth watching?

0 stock analysts on Stockchase covered Quest Diagnostics Inc. In the last year. It is a trending stock that is worth watching.

What is Quest Diagnostics Inc. stock price?

On 2022-11-22, Quest Diagnostics Inc. (DGX-N) stock closed at a price of $146.7.